Market Place
Sourcing Support
Biocytogen And Acepodia To Advance Bispecific Antibody, ADCs
07 Jan 2025 //
BUSINESSWIRE
Acepodia Announces FDA Clearance in IgG4-Related Disease
15 Nov 2024 //
PR NEWSWIRE
Acepodia and Pfizer Collaborate to Advance Chemistry-Based Cell Therapies
03 Sep 2024 //
FIERCE BIOTECH
Acepodia Announces FDA Clearance of Investigational NDA for ACE2016
04 Feb 2024 //
PR NEWSWIRE
Nobel laureate Carolyn Bertozzi joins cancer-focused Acepodia
18 Sep 2023 //
FIERCE BIOTECH
Acepodia picks up strong hand for cell therapies in $100M raise
06 Jun 2023 //
FIERCE BIOTECH
Acepodia to Present Data of Gamma Delta T cell Therapy Candidate, ACE2016
27 Mar 2023 //
PR NEWSWIRE
Acepodia Raises $109 Million Series C Financing to Advance Development
02 Dec 2021 //
GLOBENEWSWIRE
Acepodia lines pockets with $109M for oncology cell therapies
02 Dec 2021 //
FIERCEBIOTECH
Acepodia Presents Interim Phase 1 Feasibility Data for ACE1702
16 Sep 2021 //
GLOBENEWSWIRE
Acepodia to Present Data from Preclinical and Phase 1 Studies of ACE1702
13 Sep 2021 //
GLOBENEWSWIRE
Acepodia Publishes Preclinical Data on ACE1702
07 Jun 2021 //
GLOBENEWSWIRE
Acepodia Presents Data on its Allogeneic Killer-Like -Delta T Cell Therapy
18 May 2021 //
GLOBENEWSWIRE
Acepodia to Present Late-breaking Poster Supporting the Potential of its NK Cell
09 Nov 2020 //
GLOBENEWSWIRE
Acepodia to Deliver Late-breaking Poster Present at The Society Immunotherapy
02 Nov 2020 //
GLOBENEWSWIRE
Acepodia Initiates a Ph 1 Clinical Trial Evaluating Allogeneic NK Cell ACE1702
18 Aug 2020 //
GLOBENEWSWIRE
Acepodia & JW Enter into Option and License Agreement for Off-the-shelf NK
14 Jul 2020 //
GLOBENEWLSWIRE
Acepodia Provides Corporate Update & Unveils New Preclinical Allogeneic NK Cell
08 Jun 2020 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.